Abstract: OBJECTIVE To elucidate the multicomponent-multitarget-multipathway nature of Qingfei mixture using network pharmacology strategy and to provide a theoretical basis for further study on the pharmacodynamic basis and action mechanisms of Qingfei mixture against lung cancer. METHODS The active components with oral bioavailability(≥ 30%), Caco-2 cell permeability(≥ -0.4) and drug-like analysis(≥ 0.18) in Qingfei mixture were screened by searching TCMSP database. TCMSP, STITCH and Swiss databases were used to predict the targets of active components; the lung cancer disease-related genes were screened by TCMSP, TTD, and PharmGKB databases; the "active component-target-disease" network was constructed using Cytoscape software; the protein interaction analysis was performed using String database and a PPI network was established; DAVID database was used for GO function annotation and KEGG pathway enrichment analysis. RESULTS After screening, 108 active components of Qingfei mixture were obtained and 357 corresponding targets were collected. The 412 lung cancer targets were obtained, including 38 component-disease interaction targets, which were involved in cell proliferation and apoptosis, angiogenesis, mitosis and other biological processes, and involved in multiple cancer pathways, focal adhesion pathway, vascular endothelial growth factor signaling pathway, p53 signaling pathway, ErbB signaling pathway. CONCLUSION Qingfei mixture can exert anti-lung cancer effects through the regulation of cell differentiation, proliferation, apoptosis, angiogenesis, mitosis and meiosis, and inflammatory response.